Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03284216
Other study ID # ERN_16-0193
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date December 8, 2018

Study information

Verified date December 2018
Source University of Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine whether exposure to short-term high blood glucose levels impairs exercise-induced adaptations in glucose tolerance, and whether the pattern of high blood glucose levels plays a role.


Description:

Healthy male volunteers will undergo a screening visit and four experimental trials.

Screening Visit: Having read the participant info sheet, a study investigator will discuss the project with the potential participant who will have the chance to ask any questions. Informed consent will be sought and a General Health Questionnaire will be completed. Body weight, height, and skinfold measurements will be taken. Participants will also complete an exercise test to measure V̇O2max test along with heart rate and blood pressure measurements.

Individuals eligible for inclusion in the study will then return to the lab for four experimental trials, each separated by ~1 week. Trials will be completed using a randomised, counter-balanced, cross-over design. Between experimental trials, participants will be instructed to maintain their normal diet and activity habits. During the 48 hours prior to each experimental trial participants will be instructed to refrain from vigorous exercise and alcohol. For 3 days prior to each experimental trial, participants will record their dietary intake, and wear an accelerometer and a continuous glucose monitor to measure physical activity levels and glucose control.

Experimental Trials: Participants will arrive at the laboratory in the morning (~8 am) following an overnight (~10 hour) fast from food and drink (except water) since 10pm the previous evening. Upon entering the laboratory, body composition (height, weight, waist circumference) will be assessed and a cannula will be placed into a vein in each arm (one for infusion of glucose, one for blood sampling). Resting cardiovascular measures (heart rate, blood pressure, oxygen saturation) will be collected followed by an assessment of cognitive function followed immediately by one of the four 3.5 hour interventions:

- Trial A (normoglycaemia prior to exercise): This will involve no glycaemic intervention and the participant will remain in a rested, normoglycaemic state throughout all subsequent procedures.

- Trial B (steady hyperglycaemia prior to exercise): This will involve a continuous constant-rate glucose infusion to establish a steady hyperglycaemic profile. Specifically, 1.2g/kg glucose will be infused at a constant infusion rate across 3.5 hrs (equivalent to 5.71 mg/kg/min).

- Trial C (fluctuating hyperglycaemia prior to exercise): This will involve repeated glucose injections so as to cause multiple fluctuations in glycaemia. Specifically, 1.2 g/kg glucose will be infused via 8 equal boluses every 30 minutes across 3.5 hrs (the equivalent of 0.15 g/kg per bolus infused over 3.5 minutes at a rate of 42.86 mg/kg/min) interspersed with periods of no infusion.

- Trial D (normoglycaemia, no exercise): This will be identical to trial A, except there will be no exercise bout.

After 3.5 hours, the above-described glycaemic intervention will stop, and be followed immediately by the collection of post-intervention blood samples, assessment of cardiovascular response and assessment of cognitive function. Participants will then complete an exercise bout consisting of 45 minutes of moderate intensity (70% HRmax) continuous cycling, during which energy expenditure will be measured by indirect calorimetry. Post-exercise blood samples will be collected, and catheters will be removed. Participants will be fed a meal. Before leaving the lab, they will also be provided with an evening meal to be consumed at home at 7 pm, and a breakfast and lunch meal for the following day (to be consumed at 7 am and 12 pm, respectively). Participants will then return to the laboratory for 5 minutes the afternoon after the trial day (~3 pm) to remove the accelerometer and continuous glucose monitor, marking the end of the trial.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 8, 2018
Est. primary completion date November 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Male

- Aged between 18 and 50 years.

- Body Mass Index of between 19 and 30 kg/m2.

Exclusion Criteria:

- Smoking.

- Regularly use of anti-inflammatory medication.

- More than 2 kg weight change in the last 6 months, and/or have undergone weight loss surgery.

- Previous or current cancer or chronic haematological, pulmonary, cardiac, hepatic, renal, metabolic, or gastrointestinal diseases.

- Currently engaged in moderate or vigorous exercise on more than 5 days per week.

- Contraindication to exercise.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Steady-state hyperglycemia
Experimental "diabetic like" steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion.
Fluctuating hyperglycemia
Experimental "diabetic like" fluctuating hyperglycemia will be induced via repeated intravenous glucose injections.
Behavioral:
Exercise
Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours

Locations

Country Name City State
United Kingdom University of Birmingham Birmingham West Midlands

Sponsors (1)

Lead Sponsor Collaborator
University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise-induced change in blood glucose control. In all trials, continuous glucose monitoring (CGM) will be used to assess the change in glucose control compared to baseline for 24 hours after-exercise, under diet-controlled but otherwise free-living conditions. In all trials, glucose control will be determined between the time-point immediately after exercise and 24 hours after exercise.
Secondary Hyperglycemia-induced change in inflammation. In all trials, plasma cytokine levels (IL-6, TNF-alpha, IL-1ra) will be measured at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours. In all trials, inflammation will be determined at baseline (T=0 hours) and at T=3.5 hours. The glycemic interventions take place between baseline (T=0 hours) and T=3.5 hours.
Secondary Hyperglycemia-induced change in cognitive function. In all trials, cognitive function tests (CANTAB) to measure executive functioning and verbal memory will be administered at baseline (T=0 hours) and immediately after each glycaemic intervention (T=3.5 hours). The interventions will take place between baseline (T=0 hours) and T=3.5 hours. In all trials, cognitive function will be determined at baseline (T=0 hours) and at T=3.5 hours. The glycemic interventions take place between baseline (T=0 hours) and T=3.5 hours.
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Recruiting NCT03775733 - Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia N/A
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Recruiting NCT02885909 - Inpatient Blood Glucose Control in Taichung Veterans General Hospital Phase 4
Recruiting NCT02885922 - The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
Completed NCT02012465 - Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients Early Phase 1
Withdrawn NCT01488383 - Effect of Stevioside in Postpandrial Glucose in Healthy Adults N/A
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01803568 - Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU N/A
Completed NCT01810952 - The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Phase 4
Active, not recruiting NCT01247714 - Clinical Evaluation of a Specific Enteral Diet for Diabetics N/A
Not yet recruiting NCT00846144 - The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients N/A
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Recruiting NCT00654797 - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2 Phase 2
Completed NCT00468494 - Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia? N/A
Completed NCT00394407 - Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes Phase 4